The DOI matches its Crossref record; 25 of the 26 references it cites were found in a registry or an index.
Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy
Open accessAbstract
BACKGROUND: Spinal muscular atrophy type 1 (SMA1) is a progressive, monogenic motor neuron disease with an onset during infancy that results in failure to achieve motor milestones and in death or the need for mechanical ventilation by 2 years of age. We studied functional replacement of the mutated gene encoding survival motor neuron 1 (SMN1) in this disease. METHODS: vg per kilogram). The primary outcome was safety. The secondary outcome was the time until death or the need for permanent ventilatory assistance. In exploratory analyses, we compared scores on the CHOP INTEND (Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders) scale of motor function (ranging from 0 to 64, with higher scores indicating better function) in the two cohorts and motor milestones in the high-dose cohort with scores in studies of the natural history of the disease (historical cohorts). RESULTS: As of the data cutoff on August 7, 2017, all 15 patients were alive and event-free at 20 months of age, as compared with a rate of survival of 8% in a historical cohort. In the high-dose cohort, a rapid increase from baseline in the score on the CHOP INTEND scale followed gene delivery, with an increase of 9.8 points at 1 month and 15.4 points at 3 months, as compared with a decline in this score in a historical cohort. Of the 12 patients who had received the high dose, 11 sat unassisted, 9 rolled over, 11 fed orally and could speak, and 2 walked independently. Elevated serum aminotransferase levels occurred in 4 patients and were attenuated by prednisolone. CONCLUSIONS: In patients with SMA1, a single intravenous infusion of adeno-associated viral vector containing DNA coding for SMN resulted in longer survival, superior achievement of motor milestones, and better motor function than in historical cohorts. Further studies are necessary to confirm the safety and efficacy of this gene therapy. (Funded by AveXis and others; ClinicalTrials.gov number, NCT02122952 .).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Notably, the FDA has approved AAV for gene replacement therapy in spinal muscular atrophy and congenital blindness, and clinical trials are in progress 58 .”
From The promise and challenge of therapeutic genome editing (2020) · cites this paper as [58]
In the citing paper
“preclinical and clinical studies have demonstrated dose-dependent inflammation, which can reduce efficacy and lead to dose-limiting toxicity (2–8)”
From Engineering adeno-associated viral vectors to evade innate immune and inflammatory responses (2021) · cites this paper as [4]
In the citing paper
“Although neuroimaging is typically more expensive than EEG and studies are limited by issues of replication, sometimes that is related to head motion that occurred during the scan which can erode signal 61”
From Autism spectrum disorder (2020) · cites this paper as [61]
In the citing paper
“Especially considering the ability of the recombinant AAV genome to persist as an episome in post-mitotic cells, such as neurons, which ensures long-term expression even after a single administration [130-132].”
From Circumventing the packaging limit of AAV-mediated gene replacement therapy for neurological disorders (2022) · cites this paper as [132]
In the citing paper
“With AAV9’s inherent ability to target motor neurons, AAV9-based Zolgensma® for the treatment of SMA has been established as the first FDA-approved drug for systemic gene therapy in CNS diseases [171].”
From Designing and optimizing AAV-mediated gene therapy for neurodegenerative diseases: from bench to bedside (2024) · cites this paper as [171]
12 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
1 retracted
Foust, K. D., Wang, X., McGovern, V. L., Braun, L., Bevan, A. K., Haidet, A. M., Le, T. T., Morales, P. R., Rich, M. M., Burghes, A. H. M., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1610 · Cited by 688
Self-citationRetractedDeaths: preliminary data for 2003.
Hoyert, D. L., Kung, H.-C., & Smith, B. L. (2005) · PubMed · Cited by 1,649
Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes
Foust, K. D., Nurre, E., Montgomery, C. L., Hernandez, A., Chan, C. M., & Kaspar, B. K. (2009) · Nature Biotechnology · doi:10.1038/nbt.1515 · Cited by 1,456
Self-citationBayley Scales of Infant and Toddler Development, Third Edition
Bayley, N. (2012) · PsycTESTS Dataset · doi:10.1037/t14978-000 · Cited by 1,175
National Vital Statistics Reports NCHS.pdf
Hoyert, D. (2012) · Medical Entomology and Zoology · Cited by 982
Consensus Statement for Standard of Care in Spinal Muscular Atrophy
Wang, C. H., Finkel, R. S., Bertini, E. S., Schroth, M., Simonds, A., Wong, B., Aloysius, A., Morrison, L., Main, M., Crawford, T. O., et al. (2007) · Journal of Child Neurology · doi:10.1177/0883073807305788 · Cited by 961 · cited 4×
“Viral upper respiratory tract infection 0 0 3 3 (25) 3 3 (20)”
InfluentialAntisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model
Hua, Y., Sahashi, K., Hung, G., Rigo, F., Passini, M. A., Bennett, C. F., & Krainer, A. R. (2010) · Genes & Development · doi:10.1101/gad.1941310 · Cited by 664
Sugarman, E. A., Nagan, N., Zhu, H., Akmaev, V. R., Zhou, Z., Rohlfs, E. M., Flynn, K., Hendrickson, B. C., Scholl, T., Sirko-Osadsa, D. A., et al. (2012) · European Journal of Human Genetics · doi:10.1038/ejhg.2011.134 · Cited by 661
Passini, M. A., Bu, J., Richards, A. M., Kinnecom, C., Sardi, S. P., Stanek, L. M., Hua, Y., Rigo, F., Matson, J., Hung, G., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3001777 · Cited by 547
de Onis, M., Onyango, A. W., Van den Broeck, J., Chumlea, W. C., & Martorell, R. (2004) · Food and Nutrition Bulletin · doi:10.1177/15648265040251s105 · Cited by 529
Research works printed but not linked: 1
- Hoyert DL, 2012, Natl Vital Stat Rep, 61, 1
Cited by
Adeno-associated virus vector as a platform for gene therapy delivery
Wang, D., Tai, P. W. L., & Gao, G. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0012-9 · Cited by 2,444
Lord, C., Brugha, T. S., Charman, T., Cusack, J., Dumas, G., Frazier, T., Jones, E. J. H., Jones, R. M., Pickles, A., State, M. W., et al. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0138-4 · Cited by 1,859
Dunbar, C. E., High, K. A., Joung, J. K., Kohn, D. B., Ozawa, K., & Sadelain, M. (2018) · Science · doi:10.1126/science.aan4672 · Cited by 1,410
“Spinal muscular atrophy AAV9-SMN (107) Nationwide Children's”
InfluentialViral vector platforms within the gene therapy landscape
Bulcha, J. T., Wang, Y., Ma, H., Tai, P. W. L., & Gao, G. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00487-6 · Cited by 1,404
Drug delivery systems for RNA therapeutics
Paunovska, K., Loughrey, D., & Dahlman, J. E. (2022) · Nature Reviews Genetics · doi:10.1038/s41576-021-00439-4 · Cited by 1,349
Engineering adeno-associated virus vectors for gene therapy
Li, C., & Samulski, R. J. (2020) · Nature Reviews Genetics · doi:10.1038/s41576-019-0205-4 · Cited by 1,175
Gene therapy clinical trials worldwide to 2012 – an update
Ginn, S. L., Alexander, I. E., Edelstein, M. L., Abedi, M. R., & Wixon, J. (2013) · The Journal of Gene Medicine · doi:10.1002/jgm.2698 · Cited by 1,159
The promise and challenge of therapeutic genome editing
Doudna, J. A. (2020) · Nature · doi:10.1038/s41586-020-1978-5 · Cited by 1,126
Chehelgerdi, M., Chehelgerdi, M., Allela, O. Q. B., Pecho, R. D. C., Jayasankar, N., Rao, D. P., Thamaraikani, T., Vasanthan, M., Viktor, P., Lakshmaiya, N., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01865-0 · Cited by 1,062
Platt, F. M., d’Azzo, A., Davidson, B. L., Neufeld, E. F., & Tifft, C. J. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0025-4 · Cited by 1,052
Neufeld, E. F. (1991) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.60.070191.001353 · Cited by 900
Gene therapy clinical trials worldwide to 2017: An update
Ginn, S. L., Amaya, A. K., Alexander, I. E., Edelstein, M., & Abedi, M. R. (2018) · The Journal of Gene Medicine · doi:10.1002/jgm.3015 · Cited by 903
Emerging issues in AAV-mediated in vivo gene therapy
Colella, P., Ronzitti, G., & Mingozzi, F. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2017.11.007 · Cited by 881
“One solution to the issue could be to administer an immunosuppression regimen up front for all subjects, as recently performed for other diseases.(29,68) However, this is not an ideal solution to the problem because not all individuals may have an immune response to the vector, and the timing of immune responses may v…”
BackgroundAdeno-associated virus as a delivery vector for gene therapy of human diseases
Wang, J.-H., Gessler, D. J., Zhan, W., Gallagher, T. L., & Gao, G. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01780-w · Cited by 904
Hinderer, C., Katz, N., Buza, E. L., Dyer, C., Goode, T., Bell, P., Richman, L. K., & Wilson, J. M. (2018) · Human Gene Therapy · doi:10.1089/hum.2018.015 · Cited by 814
“14,32 The timing of these abnormalities could have different prognostic implications.”
Current clinical applications of in vivo gene therapy with AAVs
Mendell, J. R., Al-Zaidy, S. A., Rodino-Klapac, L. R., Goodspeed, K., Gray, S. J., Kay, C. N., Boye, S. L., Boye, S. E., George, L. A., Salabarria, S., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2020.12.007 · Cited by 743
Self-citationFinkel, R. S., Mercuri, E., Meyer, O. H., Simonds, A. K., Schroth, M. K., Graham, R. J., Kirschner, J., Iannaccone, S. T., Crawford, T. O., Woods, S., et al. (2018) · Neuromuscular Disorders · doi:10.1016/j.nmd.2017.11.004 · Cited by 684
“Other approaches, such as small molecules aiming to increase SMN protein level or SMN1 gene replacement using viral vector, are also being used in clinical trials with promising preliminary results [43] and in the next few years the scenario is likely to rapidly change.”
AAV Vector Immunogenicity in Humans: A Long Journey to Successful Gene Transfer
Costa Verdera, H., Kuranda, K., & Mingozzi, F. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2019.12.010 · Cited by 641
“Thus, immune-mediated liver toxicities can be encountered any time an AAV vector is given in a high dose and systemically.(186)”
BackgroundChemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs
Shen, X., & Corey, D. R. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx1239 · Cited by 632
Therapeutic Antisense Oligonucleotides Are Coming of Age
Bennett, C. F. (2019) · Annual Review of Medicine · doi:10.1146/annurev-med-041217-010829 · Cited by 579
High, K. A., & Roncarolo, M. G. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1706910 · Cited by 555
Gene editing restores dystrophin expression in a canine model of Duchenne muscular dystrophy
Amoasii, L., Hildyard, J. C. W., Li, H., Sanchez-Ortiz, E., Mireault, A., Caballero, D., Harron, R., Stathopoulou, T.-R., Massey, C., Shelton, J. M., et al. (2018) · Science · doi:10.1126/science.aau1549 · Cited by 546
Therapeutic in vivo delivery of gene editing agents
Raguram, A., Banskota, S., & Liu, D. R. (2022) · Cell · doi:10.1016/j.cell.2022.03.045 · Cited by 522
“, 2021), and in FDAapproved therapies (Mendell et al., 2017; Russell et al., 2017), they are currently the most popular viral vectors for delivering macromolecular therapeutics encoded as DNA.”
BackgroundMead, R. J., Shan, N., Reiser, H. J., Marshall, F., & Shaw, P. J. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00612-2 · Cited by 505
Day, J. W., Finkel, R. S., Chiriboga, C. A., Connolly, A. M., Crawford, T. O., Darras, B. T., Iannaccone, S. T., Kuntz, N. L., Peña, L. D. M., Shieh, P. B., et al. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00001-6 · Cited by 494
Self-citationSystemic AAV Micro-dystrophin Gene Therapy for Duchenne Muscular Dystrophy
Duan, D. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.07.011 · Cited by 489
Levy, J. M., Yeh, W.-H., Pendse, N., Davis, J. R., Hennessey, E., Butcher, R., Koblan, L. W., Comander, J., Liu, Q., & Liu, D. R. (2020) · Nature Biomedical Engineering · doi:10.1038/s41551-019-0501-5 · Cited by 477
Current applications and future perspective of CRISPR/Cas9 gene editing in cancer
Wang, S.-W., Gao, C., Zheng, Y.-M., Yi, L., Lu, J.-C., Huang, X.-Y., Cai, J.-B., Zhang, P.-F., Cui, Y.-H., & Ke, A.-W. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01518-8 · Cited by 478
Entering the Modern Era of Gene Therapy
Anguela, X. M., & High, K. A. (2019) · Annual Review of Medicine · doi:10.1146/annurev-med-012017-043332 · Cited by 471
“Using the same systemic intravenous administration of AAV9, these investigators subsequently showed robust efficacy in a phase I trial for the treatment of spinal muscular atrophy type 1 (SMA1) in 15 patients (72).”
BackgroundMultiyear Follow-up of AAV5-hFVIII-SQ Gene Therapy for Hemophilia A
Pasi, K. J., Rangarajan, S., Mitchell, N., Lester, W., Symington, E., Madan, B., Laffan, M., Russell, C. B., Li, M., Pierce, G. F., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1908490 · Cited by 448
Risdiplam in Type 1 Spinal Muscular Atrophy
Baranello, G., Darras, B. T., Day, J. W., Deconinck, N., Klein, A., Masson, R., Mercuri, E., Rose, K., El-Khairi, M., Gerber, M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2009965 · Cited by 436
Mercuri, E., Sumner, C. J., Muntoni, F., Darras, B. T., & Finkel, R. S. (2022) · Nature Reviews Disease Primers · doi:10.1038/s41572-022-00380-8 · Cited by 430
Goertsen, D., Flytzanis, N. C., Goeden, N., Chuapoco, M. R., Cummins, A., Chen, Y., Fan, Y., Zhang, Q., Sharma, J., Duan, Y., et al. (2022) · Nature Neuroscience · doi:10.1038/s41593-021-00969-4 · Cited by 420
Emerging insights into the complex genetics and pathophysiology of amyotrophic lateral sclerosis
Goutman, S. A., Hardiman, O., Al-Chalabi, A., Chió, A., Savelieff, M. G., Kiernan, M. C., & Feldman, E. L. (2022) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00414-2 · Cited by 401
Mendell, J. R., Sahenk, Z., Lehman, K., Nease, C., Lowes, L. P., Miller, N. F., Iammarino, M. A., Alfano, L. N., Nicholl, A., Al-Zaidy, S., et al. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2020.1484 · Cited by 405
Self-citationBlood-Brain Barrier and Delivery of Protein and Gene Therapeutics to Brain
Pardridge, W. M. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00373 · Cited by 405
Recent progress in targeted delivery vectors based on biomimetic nanoparticles
Chen, L., Hong, W., Ren, W., Xu, T., Qian, Z., & He, Z. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00631-2 · Cited by 374
Therapeutic AAV Gene Transfer to the Nervous System: A Clinical Reality
Hudry, E., & Vandenberghe, L. H. (2019) · Neuron · doi:10.1016/j.neuron.2019.02.017 · Cited by 369
Human Immune Responses to Adeno-Associated Virus (AAV) Vectors
Ronzitti, G., Gross, D.-A., & Mingozzi, F. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00670 · Cited by 357
“After this first observation, prophylactic corticosteroids treatment was applied (30 days, starting 1 day before vector infusion) and ALT elevation was reported only in 3 patients within the high dose group (125).”
BackgroundInfluentialTherapies for rare diseases: therapeutic modalities, progress and challenges ahead
Tambuyzer, E., Vandendriessche, B., Austin, C. P., Brooks, P. J., Larsson, K., Miller Needleman, K. I., Valentine, J., Davies, K., Groft, S. C., Preti, R., et al. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0049-9 · Cited by 357
Comprehensive AAV capsid fitness landscape reveals a viral gene and enables machine-guided design
Ogden, P. J., Kelsic, E. D., Sinai, S., & Church, G. M. (2019) · Science · doi:10.1126/science.aaw2900 · Cited by 356
Onasemnogene Abeparvovec: First Global Approval
Hoy, S. M. (2019) · Drugs · doi:10.1007/s40265-019-01162-5 · Cited by 337
Leborgne, C., Barbon, E., Alexander, J. M., Hanby, H., Delignat, S., Cohen, D. M., Collaud, F., Muraleetharan, S., Lupo, D., Silverberg, J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0911-7 · Cited by 336
CRISPR/Cas9 for cancer research and therapy
Zhan, T., Rindtorff, N., Betge, J., Ebert, M. P., & Boutros, M. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.04.001 · Cited by 328
Keeler, A. M., & Flotte, T. R. (2019) · Annual Review of Virology · doi:10.1146/annurev-virology-092818-015530 · Cited by 322
Strauss, K. A., Farrar, M. A., Muntoni, F., Saito, K., Mendell, J. R., Servais, L., McMillan, H. J., Finkel, R. S., Swoboda, K. J., Kwon, J. M., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01866-4 · Cited by 316
Self-citationThe use of viral vectors in vaccine development
Travieso, T., Li, J., Mahesh, S., Mello, J. D. F. R. E., & Blasi, M. (2022) · npj Vaccines · doi:10.1038/s41541-022-00503-y · Cited by 310
Gene therapy for neurological disorders: progress and prospects
Deverman, B. E., Ravina, B. M., Bankiewicz, K. S., Paul, S. M., & Sah, D. W. Y. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.110 · Cited by 306
Deep diversification of an AAV capsid protein by machine learning
Bryant, D. H., Bashir, A., Sinai, S., Jain, N. K., Ogden, P. J., Riley, P. F., Church, G. M., Colwell, L. J., & Kelsic, E. D. (2021) · Nature Biotechnology · doi:10.1038/s41587-020-00793-4 · Cited by 300
Mendell, J. R., Al-Zaidy, S. A., Lehman, K. J., McColly, M., Lowes, L. P., Alfano, L. N., Reash, N. F., Iammarino, M. A., Church, K. R., Kleyn, A., et al. (2021) · JAMA Neurology · doi:10.1001/jamaneurol.2021.1272 · Cited by 295
Self-citationRisdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls
Darras, B. T., Masson, R., Mazurkiewicz-Bełdzińska, M., Rose, K., Xiong, H., Zanoteli, E., Baranello, G., Bruno, C., Vlodavets, D., Wang, Y., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2102047 · Cited by 284
Strauss, K. A., Farrar, M. A., Muntoni, F., Saito, K., Mendell, J. R., Servais, L., McMillan, H. J., Finkel, R. S., Swoboda, K. J., Kwon, J. M., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01867-3 · Cited by 286
Self-citationThe delivery challenge: fulfilling the promise of therapeutic genome editing
van Haasteren, J., Li, J., Scheideler, O. J., Murthy, N., & Schaffer, D. V. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0565-5 · Cited by 285
Schorling, D. C., Pechmann, A., & Kirschner, J. (2020) · Journal of Neuromuscular Diseases · doi:10.3233/jnd-190424 · Cited by 276
“The first clinical trial with zolgensma (AVXS-101) included 15 infants with SMA type 1 with 2 SMN2 copies (<8 months of age) [53].”
MethodLogroscino, G., Piccininni, M., Marin, B., Nichols, E., Abd-Allah, F., Abdelalim, A., Alahdab, F., Asgedom, S. W., Awasthi, A., Chaiah, Y., et al. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30404-6 · Cited by 272
Disruption of RNA Metabolism in Neurological Diseases and Emerging Therapeutic Interventions
Nussbacher, J. K., Tabet, R., Yeo, G. W., & Lagier-Tourenne, C. (2019) · Neuron · doi:10.1016/j.neuron.2019.03.014 · Cited by 272
“SMN repletion was also successfully achieved in patients using an adeno-associated virus (AAV)-mediated gene therapy approach (Figure 2Aiv) (Mendell et al., 2017), altogether demonstrating that restoration of SMN protein level is therapeutic (Groen et al.”
MethodDrug Repurposing for Rare Diseases
Roessler, H. I., Knoers, N. V. A. M., van Haelst, M. M., & van Haaften, G. (2021) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2021.01.003 · Cited by 269
Meliani, A., Boisgerault, F., Hardet, R., Marmier, S., Collaud, F., Ronzitti, G., Leborgne, C., Costa Verdera, H., Simon Sola, M., Charles, S., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06621-3 · Cited by 265
Mercuri, E., Muntoni, F., Baranello, G., Masson, R., Boespflug-Tanguy, O., Bruno, C., Corti, S., Daron, A., Deconinck, N., Servais, L., et al. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00251-9 · Cited by 261
Capsid modifications for targeting and improving the efficacy of AAV vectors
Büning, H., & Srivastava, A. (2019) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2019.01.008 · Cited by 260
“AAV9 vectors have been successfully used in gene therapy for Pompe disease(28) and showed impressive efficacy in gene therapy for spinal muscular atrophy.(29) The AAV1-LPL vector was approved as a drug designated alipogene tiparvovec and marketed under the trade name Glybera in Europe in 2012.”
MethodWirth, B., Karakaya, M., Kye, M. J., & Mendoza-Ferreira, N. (2020) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-102319-103602 · Cited by 255
CRISPR-Cas9 corrects Duchenne muscular dystrophy exon 44 deletion mutations in mice and human cells
Min, Y.-L., Li, H., Rodriguez-Caycedo, C., Mireault, A. A., Huang, J., Shelton, J. M., McAnally, J. R., Amoasii, L., Mammen, P. P. A., Bassel-Duby, R., et al. (2019) · Science Advances · doi:10.1126/sciadv.aav4324 · Cited by 251
Erratum: Gene therapy for neurological disorders: progress and prospects
Deverman, B. E., Ravina, B. M., Bankiewicz, K. S., Paul, S. M., & Sah, D. W. Y. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.158 · Cited by 248
Advances in therapy for spinal muscular atrophy: promises and challenges
Groen, E. J. N., Talbot, K., & Gillingwater, T. H. (2018) · Nature Reviews Neurology · doi:10.1038/nrneurol.2018.4 · Cited by 235
Colasante, G., Lignani, G., Brusco, S., Di Berardino, C., Carpenter, J., Giannelli, S., Valassina, N., Bido, S., Ricci, R., Castoldi, V., et al. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2019.08.018 · Cited by 231
Huang, Q., Chan, K. Y., Tobey, I. G., Chan, Y. A., Poterba, T., Boutros, C. L., Balazs, A. B., Daneman, R., Bloom, J. M., Seed, C., et al. (2019) · PLOS ONE · doi:10.1371/journal.pone.0225206 · Cited by 234
Genomics, convergent neuroscience and progress in understanding autism spectrum disorder
Willsey, H. R., Willsey, A. J., Wang, B., & State, M. W. (2022) · Nature Reviews Neuroscience · doi:10.1038/s41583-022-00576-7 · Cited by 229
Treatment Algorithm for Infants Diagnosed with Spinal Muscular Atrophy through Newborn Screening
Glascock, J., Sampson, J., Haidet-Phillips, A., Connolly, A., Darras, B., Day, J., Finkel, R., Howell, R. R., Klinger, K., Kuntz, N., et al. (2018) · Journal of Neuromuscular Diseases · doi:10.3233/jnd-180304 · Cited by 233
Self-citationEfficient prime editing in mouse brain, liver and heart with dual AAVs
Davis, J. R., Banskota, S., Levy, J. M., Newby, G. A., Wang, X., Anzalone, A. V., Nelson, A. T., Chen, P. J., Hennes, A. D., An, M., et al. (2024) · Nature Biotechnology · doi:10.1038/s41587-023-01758-z · Cited by 227
“Adeno-associated viruses (AAVs) are clinically validated and FDA approved for in vivo gene therapy and gene editing applications 22,23 .”
BackgroundMethodTreatment of a Mouse Model of ALS by In Vivo Base Editing
Lim, C. K. W., Gapinske, M., Brooks, A. K., Woods, W. S., Powell, J. E., Zeballos C., M. A., Winter, J., Perez-Pinera, P., & Gaj, T. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.01.005 · Cited by 222
A Historical Review of Brain Drug Delivery
Pardridge, W. M. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14061283 · Cited by 219
Jüttner, J., Szabo, A., Gross-Scherf, B., Morikawa, R. K., Rompani, S. B., Hantz, P., Szikra, T., Esposti, F., Cowan, C. S., Bharioke, A., et al. (2019) · Nature Neuroscience · doi:10.1038/s41593-019-0431-2 · Cited by 218
“AAVs fulfill these criteria and are showing promise in clinical and pre-clinical gene therapy studies for inherited monogenic and complex eye diseases (Mendell et al., 2017; Russell et al., 2017).”
BackgroundThe GPI-Linked Protein LY6A Drives AAV-PHP.B Transport across the Blood-Brain Barrier
Hordeaux, J., Yuan, Y., Clark, P. M., Wang, Q., Martino, R. A., Sims, J. J., Bell, P., Raymond, A., Stanford, W. L., & Wilson, J. M. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.02.013 · Cited by 217
“An AAV9-based vector approach to target motor neurons of patients with spinal muscular atrophy resulted in improvedmotor function and prolonged survival.(6) Similarly, impressive results have been achieved following i.”
Health outcomes in spinal muscular atrophy type 1 following AVXS-101 gene replacement therapy
Al‐Zaidy, S., Pickard, A. S., Kotha, K., Alfano, L. N., Lowes, L., Paul, G., Church, K., Lehman, K., Sproule, D. M., Dabbous, O., et al. (2019) · Pediatric Pulmonology · doi:10.1002/ppul.24203 · Cited by 216
Self-citationEngineering adeno-associated viral vectors to evade innate immune and inflammatory responses
Chan, Y. K., Wang, S. K., Chu, C. J., Copland, D. A., Letizia, A. J., Costa Verdera, H., Chiang, J. J., Sethi, M., Wang, M. K., Neidermyer, W. J., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abd3438 · Cited by 215
George, L. A., Ragni, M. V., Rasko, J. E. J., Raffini, L. J., Samelson-Jones, B. J., Ozelo, M., Hazbon, M., Runowski, A. R., Wellman, J. A., Wachtel, K., et al. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.06.001 · Cited by 213
Chitosan for gene delivery: Methods for improvement and applications
Chuan, D., Jin, T., Fan, R., Zhou, L., & Guo, G. (2019) · Advances in Colloid and Interface Science · doi:10.1016/j.cis.2019.03.007 · Cited by 212
Overcoming innate immune barriers that impede AAV gene therapy vectors
Muhuri, M., Maeda, Y., Ma, H., Ram, S., Fitzgerald, K. A., Tai, P. W. L., & Gao, G. (2021) · Journal of Clinical Investigation · doi:10.1172/jci143780 · Cited by 212
Spinal muscular atrophy — insights and challenges in the treatment era
Mercuri, E., Pera, M. C., Scoto, M., Finkel, R., & Muntoni, F. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-00413-4 · Cited by 206
Charcot-Marie-Tooth: From Molecules to Therapy
Morena, J., Gupta, A., & Hoyle, J. C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20143419 · Cited by 206
“Gene replacement is a very promising technology, particularly given the recent clinical success of single dose intrathecal gene replacement therapy for spinal muscular atrophy [87].”
BackgroundMoving Forward After Two Deaths in a Gene Therapy Trial of Myotubular Myopathy
Wilson, J. M., & Flotte, T. R. (2020) · Human Gene Therapy · doi:10.1089/hum.2020.182 · Cited by 203
Engineered materials for in vivo delivery of genome-editing machinery
Tong, S., Moyo, B., Lee, C. M., Leong, K., & Bao, G. (2019) · Nature Reviews Materials · doi:10.1038/s41578-019-0145-9 · Cited by 205
AAV-based in vivo gene therapy for neurological disorders
Ling, Q., Herstine, J. A., Bradbury, A., & Gray, S. J. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00766-7 · Cited by 197
“One of the most commonly used AAVs for CNS tissue is AAV9, which has been applied in at least 15 clinical trials 31 , such as for giant axonal neuropathy 32,33 and the FDA-approved therapy for SMA 34 .”
BackgroundMethodInfluentialGene regulatory programmes of tissue regeneration
Goldman, J. A., & Poss, K. D. (2020) · Nature Reviews Genetics · doi:10.1038/s41576-020-0239-7 · Cited by 200
Gene Therapy for Duchenne Muscular Dystrophy
Elangkovan, N., & Dickson, G. (2021) · Journal of Neuromuscular Diseases · doi:10.3233/jnd-210678 · Cited by 196
“vg per kilogram, has provided proof-of-principle for systemic gene transfer using AAV in humans [19, 51].”
BackgroundAn AAV capsid reprogrammed to bind human transferrin receptor mediates brain-wide gene delivery
Huang, Q., Chan, K. Y., Wu, J., Botticello-Romero, N. R., Zheng, Q., Lou, S., Keyes, C., Svanbergsson, A., Johnston, J., Mills, A., et al. (2024) · Science · doi:10.1126/science.adm8386 · Cited by 197
Ramakrishna, K., Nalla, L. V., Naresh, D., Venkateswarlu, K., Viswanadh, M. K., Nalluri, B. N., Chakravarthy, G., Duguluri, S., Singh, P., Rai, S. N., et al. (2023) · Diseases · doi:10.3390/diseases11030089 · Cited by 192
“Pulmonary, gastrointestinal, and orthopedic supportive care [249–251], along with drugs like nusinersen [252], onasemnogene abeparvovec [253], risdiplam [254], and botulinum toxin [255], are used for the treatment of SMA.”
BackgroundRNA Dysregulation in Amyotrophic Lateral Sclerosis
Butti, Z., & Patten, S. A. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2018.00712 · Cited by 197
“An ASO therapy based (nusinersen) approach designed to promote exon skipping has proven to be very effective in treating spinal muscular atrophy (SMA) in clinical trials (Chiriboga et al., 2016; Finkel et al., 2016; Mendell et al., 2017; Scoto et al., 2017).”
BackgroundDangouloff, T., & Servais, L. (2019) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s172291 · Cited by 196
“2 months).(21,22) Patients treated before the age of 3 months acquired the sitting position (>5 s) at a mean age of 9.”
BackgroundDavis, J. R., Wang, X., Witte, I. P., Huang, T. P., Levy, J. M., Raguram, A., Banskota, S., Seidah, N. G., Musunuru, K., & Liu, D. R. (2022) · Nature Biomedical Engineering · doi:10.1038/s41551-022-00911-4 · Cited by 192
Varcianna, A., Myszczynska, M. A., Castelli, L. M., O'Neill, B., Kim, Y., Talbot, J., Nyberg, S., Nyamali, I., Heath, P. R., Stopford, M. J., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2018.11.067 · Cited by 194
Age-dependent SMN expression in disease-relevant tissue and implications for SMA treatment
Ramos, D. M., d’Ydewalle, C., Gabbeta, V., Dakka, A., Klein, S. K., Norris, D. A., Matson, J., Taylor, S. J., Zaworski, P. G., Prior, T. W., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci124120 · Cited by 190
“hyde for 24 hours at 4°C, washed 3 × 10 minutes in PBS, and stored in range of clinical efficacy, with the time of treatment initiation playing a critical role in the magnitude of clinical response (16, 17, 52).”
BackgroundMethodSelf-citationMultifaceted roles of APOE in Alzheimer disease
Jackson, R. J., Hyman, B. T., & Serrano-Pozo, A. (2024) · Nature Reviews Neurology · doi:10.1038/s41582-024-00988-2 · Cited by 193
“Gene therapy has already been efficacious in other neurodegenerative diseases, most notably spinal muscular atrophy 200,201 .”
Emerging roles of ATG7 in human health and disease
Collier, J. J., Suomi, F., Oláhová, M., McWilliams, T. G., & Taylor, R. W. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202114824 · Cited by 193
“This approach has, however, yielded success for the treatment of spinal muscular atrophy, a progressive motor neuron disease (Mendell et al, 2017).”
BackgroundViral Vectors in Gene Therapy: Where Do We Stand in 2023?
Lundstrom, K. (2023) · Viruses · doi:10.3390/v15030698 · Cited by 187
“In another phase I study, a single intra ‐ venous AAV9 ‐ SMN injection improved motor function and extended survival in SMA patients [231].”
Gene therapy for neurodegenerative disorders: advances, insights and prospects
Chen, W., Hu, Y., & Ju, D. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.01.015 · Cited by 187
Gene therapy for ALS: A review
Amado, D. A., & Davidson, B. L. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.04.008 · Cited by 184
Gain of toxic function by long-term AAV9-mediated SMN overexpression in the sensorimotor circuit
Van Alstyne, M., Tattoli, I., Delestrée, N., Recinos, Y., Workman, E., Shihabuddin, L. S., Zhang, C., Mentis, G. Z., & Pellizzoni, L. (2021) · Nature Neuroscience · doi:10.1038/s41593-021-00827-3 · Cited by 188
“However, unlike these early-onset adverse events likely associated with systemic exposure to high doses of AAV9 in peripheral organs 16,20,45 , the neurotoxic effects leading to late-onset synaptic loss and neuronal death as well as progressive sensory-motor dysfunction that we document here are…”
InfluentialOne Year of Newborn Screening for SMA – Results of a German Pilot Project
Vill, K., Kölbel, H., Schwartz, O., Blaschek, A., Olgemöller, B., Harms, E., Burggraf, S., Röschinger, W., Durner, J., Gläser, D., et al. (2019) · Journal of Neuromuscular Diseases · doi:10.3233/jnd-190428 · Cited by 187
Gene-based therapies for neurodegenerative diseases
Sun, J., & Roy, S. (2021) · Nature Neuroscience · doi:10.1038/s41593-020-00778-1 · Cited by 187
Metadata
- Authors
- Mendell, J. R., Al-Zaidy, S., Shell, R., Arnold, W. D., Rodino-Klapac, L. R., Prior, T. W., Lowes, L., Alfano, L., Berry, K., Church, K., Kissel, J. T., Nagendran, S., L’Italien, J., Sproule, D. M., Wells, C., Cardenas, J. A., Heitzer, M. D., Kaspar, A., Corcoran, S., Braun, L., Likhite, S., Miranda, C., Meyer, K., Foust, K. D., Burghes, A. H. M., & Kaspar, B. K.
- Affiliations
- Abigail Wexner Research Institute (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-11-02
- Volume
- 377
- Issue
- 18
- Pages
- 1713-1722
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2765253110
- Cited by
- 2,381
- References
- 26
- Citations by year
- 2026: 205 · 2025: 232 · 2024: 292 · 2023: 270 · 2022: 289 · 2021: 347 · 2020: 298 · 2019: 246 · 2018: 172 · 2017: 16
- FWCI
- 115.14
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Nationwide Children's Hospital
- AveXis
- Research Institute, Nationwide Children's Hospital
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
- Keywords
- spinal muscular atrophy type 1, gene replacement therapy, adeno-associated virus vectors, SMN1, motor function, motor milestones, survival, CHOP INTEND, aminotransferase elevation, prednisolone, treatment efficacy and safety
- MeSH terms
- Dependovirus, Female, Genetic Vectors, Humans, Infant, Infant, Newborn, Infusions, Intravenous, Liver Diseases, Male, Motor Skills, Respiration, Artificial, Spinal Muscular Atrophies of Childhood, Genetic Therapy, Cohort Studies, Nutritional Support, Disease-Free Survival, Survival of Motor Neuron 1 Protein, Historically Controlled Study
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.